NeuroOne Regains Compliance With Nasdaq Minimum Bid Price Requirement

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has received notification from Nasdaq confirming the company has regained compliance with the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2), effectively closing the matter.

The company had been notified by Nasdaq on May 6, 2025, that its common stock’s closing bid price had fallen below the $1.00 per share minimum for 30 consecutive business days. Nasdaq granted a 180-day extension on November 4, 2025, giving NeuroOne until May 4, 2026, to meet the requirement.

To address the deficiency, NeuroOne implemented a 1-for-6 reverse stock split, effective at 5:00 p.m. Eastern Time on April 15, 2026. The stock began trading on a split-adjusted basis at market open on April 16, 2026, under the same ticker symbol ‘NMTC’ but with a new CUSIP number (64130M308). This action raised the per-share price above the $1.00 threshold, allowing the company to satisfy Nasdaq’s listing rules.

NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. Its product portfolio includes four FDA-cleared platforms: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures while improving patient outcomes through diagnostic and therapeutic functions. The company also has research and development programs in drug delivery, basivertebral nerve ablation, and spinal cord stimulation.

Regaining compliance is a critical step for NeuroOne to maintain its listing on the Nasdaq Capital Market, which provides access to public capital markets and investor visibility. The reverse stock split, while potentially dilutive in the short term, helps stabilize the stock price and ensures continued trading on a major exchange. Investors and stakeholders will likely view this positively as it removes the overhang of potential delisting and allows the company to focus on its operational and clinical milestones.

For more information about NeuroOne and its technologies, visit nmtc1.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is NeuroOne Regains Compliance With Nasdaq Minimum Bid Price Requirement.

The post NeuroOne Regains Compliance With Nasdaq Minimum Bid Price Requirement appeared first on citybuzz.